SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-029848
Filing Date
2023-06-14
Accepted
2023-06-14 16:31:45
Documents
12
Period of Report
2023-06-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K brhc20054327_8k.htm   iXBRL 8-K 26006
  Complete submission text file 0001140361-23-029848.txt   160935

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ocup-20230608.xsd EX-101.SCH 3865
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20230608_lab.xml EX-101.LAB 22546
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20230608_pre.xml EX-101.PRE 16044
6 EXTRACTED XBRL INSTANCE DOCUMENT brhc20054327_8k_htm.xml XML 4087
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

IRS No.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 231014562
SIC: 2834 Pharmaceutical Preparations